Publications en collaboration avec des chercheurs de University of Florence (37)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2023

  1. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

    Chest, Vol. 163, Núm. 3, pp. 586-598

2022

  1. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire

    Annals of the rheumatic diseases, Vol. 81, Núm. 4, pp. 507-515

2020

  1. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2016-2023

  2. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database

    Autoimmunity Reviews, Vol. 19, Núm. 2

  3. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

    Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694

  4. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

    The Lancet Rheumatology, Vol. 2, Núm. 2, pp. e71-e83

  5. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 10, pp. 963-974

2019

  1. Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database

    Scandinavian Journal of Rheumatology, Vol. 48, Núm. 1, pp. 42-51

  2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  3. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

2018

  1. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study

    Rheumatology (United Kingdom), Vol. 57, Núm. 2, pp. 370-381

  2. Gender differences in early systemic sclerosis patients: A report from the EULAR scleroderma trials and research group (EUSTAR) database

    Clinical and Experimental Rheumatology, Vol. 36, pp. S68-S75

  3. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations

    PLoS ONE, Vol. 13, Núm. 1

  4. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 4, pp. 563-570

  5. There is a need for new systemic sclerosis subset criteria. A content analytic approach

    Scandinavian Journal of Rheumatology, Vol. 47, Núm. 1, pp. 62-70

2017

  1. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 35, pp. S114-S121

  2. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218

  3. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

  4. What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

    Journal of Scleroderma and Related Disorders, Vol. 2, Núm. 3, pp. 169-182